Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. [PDF]
Bell R +4 more
europepmc +1 more source
Targeting Bruton's Tyrosine Kinase (BTK) in Autoimmunity: Achievements, Opportunities and Challenges. [PDF]
Torke S, Dybowski S, Weber MS.
europepmc +1 more source
Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib. [PDF]
Wang L +6 more
europepmc +1 more source
Retraction of TREM2 aggravates sepsis by inhibiting fatty acid oxidation via the SHP1/BTK axis. [PDF]
Ming S +11 more
europepmc +1 more source
Two-step mechanism of Bruton's tyrosine kinase membrane recruitment and activation. [PDF]
McAllister RA +5 more
europepmc +1 more source
Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score-Matched Real-World Analysis. [PDF]
Homeniuk A +3 more
europepmc +1 more source
Optical Coherence Tomography and Its Potential Utility in Below-the-Knee Intervention: Can "Seeing More" Outweigh Practical Technology Limitations? [PDF]
Smith H, Secemsky EA.
europepmc +1 more source
Three generations, one target: BTK inhibitors in lymphoma. [PDF]
Schmitt A, Hailfinger S.
europepmc +1 more source
Severe Central Nervous System Fungal Infection Following Tirabrutinib Administration in a Patient with Refractory Primary Central Nervous System Lymphoma: A Case Report. [PDF]
Akimoto J, Nakamura Y, Fukuhara H.
europepmc +1 more source

